William P. Peters
Directeur/Membre du Conseil chez NanoVector, Inc.
Profil
William P.
Peters is currently a Director at NanoVector, Inc. He was previously Chairman & Chief Executive Officer at Fennec Pharmaceuticals, Inc. from 2002 to 2009, President & Chief Executive Officer at Barbara Ann Karmanos Cancer Institute in 2001, Director at Intrac, Inc., Director-Bone Marrow Transplantation at Duke University from 1984 to 1995, Director at Aegera Therapeutics, Inc., Director at Javelin Pharmaceuticals, Inc. in 2005-2006, Associate Dean-Cancer at Wayne State University (Michigan), and President at VHS of Michigan, Inc. Dr. Peters holds a graduate and doctorate degree from The Trustees of Columbia University in The City of New York, an MBA degree from Duke University, and an undergraduate degree from The Pennsylvania State University.
Postes actifs de William P. Peters
| Sociétés | Poste | Début |
|---|---|---|
NanoVector, Inc.
 NanoVector, Inc. Medical SpecialtiesHealth Technology NanoVector, Inc. develops nanoparticle drug delivery system. The company was founded by Stefan Franzen and Steven Lommel on May 09, 2002 and is headquartered in Raleigh, NC. | Directeur/Membre du Conseil | - |
Anciens postes connus de William P. Peters
| Sociétés | Poste | Fin |
|---|---|---|
| FENNEC PHARMACEUTICALS INC. | Président | 01/07/2009 |
Javelin Pharmaceuticals, Inc.
 Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | 09/06/2006 |
Intrac, Inc.
 Intrac, Inc. Financial ConglomeratesFinance The Group's principal activity is to develop new drug and improve formulations of existing drug that target current unmet and underserved medical need primarily in the pain management market. It develops simple and user-friendly products, including new modes and routes of delivery for drugs optimized for relieving moderate-to-severe pain. The Group is in the development stage. | Directeur/Membre du Conseil | 09/09/2005 |
| Wayne State University (Michigan) | Corporate Officer/Principal | 01/01/2001 |
Barbara Ann Karmanos Cancer Institute
 Barbara Ann Karmanos Cancer Institute Hospital/Nursing ManagementHealth Services Barbara Ann Karmanos Cancer Institute provides health care services for cancer patients. It also provides integrated center of research, patient care and education, dedicated to the prevention, early detection, treatment and eventual eradication of cancer. The company was founded in 1943 and is headquartered in Detroit, MI. | President | 01/01/2001 |
Formation de William P. Peters
| The Pennsylvania State University | Undergraduate Degree |
| The Trustees of Columbia University in The City of New York | Doctorate Degree |
| Duke University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| FENNEC PHARMACEUTICALS INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Aegera Therapeutics, Inc.
 Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | Health Technology |
Intrac, Inc.
Intrac, Inc. Financial ConglomeratesFinance The Group's principal activity is to develop new drug and improve formulations of existing drug that target current unmet and underserved medical need primarily in the pain management market. It develops simple and user-friendly products, including new modes and routes of delivery for drugs optimized for relieving moderate-to-severe pain. The Group is in the development stage. | Finance |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | Health Technology |
VHS of Michigan, Inc.
 VHS of Michigan, Inc. Hospital/Nursing ManagementHealth Services The Detroit Medical Center's (DMC) record of service has provided medical excellence throughout the history of the Metropolitan Detroit area. From the founding of Children's Hospital in 1886, to the creation of the first mechanical heart at Harper Hospital 50 years ago. Their medical experts are nationally recognized and each year, hundreds of DMC doctors are included in the list of America's Best Doctors. A reputation for excellence draws patients to world-class programs in oncology, organ transplant, cardiology, women's services, neurosciences, stroke treatment, optometry, orthopedics, pediatrics and rehabilitation. They are the leading academically integrated system in metropolitan Detroit and the largest health care provider in southeast Michigan. The DMC has more than 2,000 licensed beds and 3,000 affiliated physicians. Detroit Medical Center facilities employ best practices and conduct business in an atmosphere of respect and professionalism. Their recognition of and attention to diversity in their business operations and healthcare services is unparalleled. Their volunteer efforts in health education & disease prevention represent an ongoing commitment to the health and well-being of the communities they serve. The DMC continues to meet the health care needs of a growing community, offering the best in medical research & development, advanced technology and optimum clinical services. | Health Services |
Barbara Ann Karmanos Cancer Institute
Barbara Ann Karmanos Cancer Institute Hospital/Nursing ManagementHealth Services Barbara Ann Karmanos Cancer Institute provides health care services for cancer patients. It also provides integrated center of research, patient care and education, dedicated to the prevention, early detection, treatment and eventual eradication of cancer. The company was founded in 1943 and is headquartered in Detroit, MI. | Health Services |
NanoVector, Inc.
NanoVector, Inc. Medical SpecialtiesHealth Technology NanoVector, Inc. develops nanoparticle drug delivery system. The company was founded by Stefan Franzen and Steven Lommel on May 09, 2002 and is headquartered in Raleigh, NC. | Health Technology |
